Berlin \u2014 SMP advi\u00adsed early-stage inves\u00adtor 42CAP on its invest\u00adment in Vien\u00adnese biotech startup Allcyte. As lead inves\u00adtor of an inter\u00adna\u00adtio\u00adnal inves\u00adtor consor\u00adtium, 42CAP inves\u00adted toge\u00adther with Air Street Capi\u00adtal (UK), Amino Coll\u00adec\u00adtive (Germany), VP Venture Part\u00adners (Switz\u00ader\u00adland) and PUSH Ventures (Austria) in the course of the growth financing.<\/p>\n
Allcyte, which specia\u00adli\u00adzes in cancer therapy, has so far used its process to treat blood cancers. Howe\u00adver, accor\u00adding to the company, expan\u00adsion to other cancer types is alre\u00adady plan\u00adned. \u201cInstead of trying to extra\u00adpo\u00adlate infor\u00adma\u00adtion from DNA, we\u2019re taking actual cancer cells and test\u00ading directly on them to see what works,\u201d Niko\u00adlas Krall, co-foun\u00adder and CEO of Allcyte<\/strong>, told U.S. Fortune maga\u00adzine. For the multi\u00adtude of rapidly perfor\u00admed \u201cmicro\u00adex\u00adpe\u00adri\u00adments,\u201d the startup uses AI image reco\u00adgni\u00adtion to deter\u00admine how cells respond to each drug.<\/p>\n \u201cIt is fasci\u00adna\u00adting to see how alre\u00adady today in modern cancer therapy the use of arti\u00adfi\u00adcial intel\u00adli\u00adgence in inter\u00adac\u00adtion with biome\u00addi\u00adcine can help to directly deter\u00admine and in this way maxi\u00admize the degree of effi\u00adcacy of diffe\u00adrent treat\u00adments and to speci\u00adfi\u00adcally advance drug deve\u00adlo\u00adp\u00adment,\u201d says Jens Kretz\u00adschmann. \u201cWe hope that this invest\u00adment has laid the foun\u00adda\u00adtion for further revo\u00adlu\u00adtio\u00adnary succes\u00adses of the company in the fight against cancer,\u201d adds Frede\u00adrik G\u00e4rtner.<\/p>\n 42CAP recei\u00adved legal and tax advice from an SMP team led by Frede\u00adrik G\u00e4rt\u00adner, Jens Kretz\u00adschmann, and Martyna Sabat. Previously, SMP assis\u00adted the venture capi\u00adta\u00adlist in a number of finan\u00adcing rounds as well as in the launch of its second venture capi\u00adtal fund generation.<\/p>\n About 42CAP<\/strong> Allcyte<\/strong> About SMP<\/strong> Consul\u00adtant 42CAP: SMP<\/strong> Berlin \u2014 SMP advi\u00adsed early-stage inves\u00adtor 42CAP on its invest\u00adment in Vien\u00adnese biotech startup Allcyte. As lead inves\u00adtor of an inter\u00adna\u00adtio\u00adnal inves\u00adtor consor\u00adtium, 42CAP inves\u00adted toge\u00adther with Air Street Capi\u00adtal (UK), Amino Coll\u00adec\u00adtive (Germany), VP Venture Part\u00adners (Switz\u00ader\u00adland) and PUSH Ventures (Austria) in the course of the growth finan\u00adcing. Allcyte, which specia\u00adli\u00adzes in cancer therapy, [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":37108,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1373],"tags":[],"class_list":["post-43493","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-venture-capital-en","news-category-venture-capital-news"],"yoast_head":"\n
\n42CAP inves\u00adtors Alex Meyer and Thomas Wilke invest very early in young compa\u00adnies with global ambi\u00adti\u00adons. They built one of Euro\u00adpe\u2019s largest SaaS compa\u00adnies them\u00adsel\u00adves with eCir\u00adcle and sold the profi\u00adta\u00adble company to Teradata (NYSE:TDC) in 2012. The 42CAP credo Peers amongst Entre\u00adpre\u00adneurs reflects their invest\u00adment approach to support data and tech\u00adno\u00adlogy-driven busi\u00adness models, product-driven foun\u00adders and sustainable busi\u00adness deve\u00adlo\u00adp\u00adment. This back\u00adground is appre\u00adcia\u00adted by foun\u00adders such as Nico\u00adlas Reboud (SHINE, Paris), Inigo Ijuan\u00adtegui (Ontruck, Madrid) and Alex\u00adan\u00adder Igels\u00adb\u00f6ck (Adve\u00adrity, Vienna).<\/p>\n
\nAllcyte is a biotech startup based in Vienna. Using AI-assis\u00adted image analy\u00adsis, Allcyte has deve\u00adlo\u00adped a method to gene\u00adrate actionable insights into the func\u00adtional acti\u00advity of drugs and drug candi\u00adda\u00adtes directly in viable, primary tissue samples from human cancer pati\u00adents at the single-cell level. The company thus enables physi\u00adci\u00adans to treat cancer pati\u00adents with the most promi\u00adsing drug at the right time, when clas\u00adsi\u00adcal gene\u00adtics-driven precis\u00adion medi\u00adcine fails to provide precise answers. It also enables phar\u00admaceu\u00adti\u00adcal compa\u00adnies to select the most promi\u00adsing drug candi\u00adda\u00adtes for clini\u00adcal deve\u00adlo\u00adp\u00adment in the right pati\u00adent popu\u00adla\u00adti\u00adons to maxi\u00admize clini\u00adcal trial success rates and pati\u00adent bene\u00adfit. Allcyte star\u00adted in 2017 as a spin-off of the Vienna-based CeMM Rese\u00adarch Center for Mole\u00adcu\u00adlar Medi\u00adcine. Foun\u00added by Berend Snij\u00adder, Gregory Vladi\u00admer, Niko\u00adlaus Krall and Giulio Superti-Furga, the company curr\u00adently employs around 30 people.<\/p>\n
\nSMP is a specia\u00adlist tax and commer\u00adcial law firm opera\u00adting in the core areas of corpo\u00adrate, funds, liti\u00adga\u00adtion, tax and tran\u00adsac\u00adtions. SMP\u2019s attor\u00adneys and tax advi\u00adsors repre\u00adsent a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. Since its foun\u00adda\u00adtion in 2017, SMP has become one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. The firm and its part\u00adners are natio\u00adnally and inter\u00adna\u00adtio\u00adnally ranked by JUVE, Best Lawy\u00aders, Legal 500, Focus, and Cham\u00adbers and Part\u00adners. Today, SMP employs more than 60 expe\u00adri\u00aden\u00adced lawy\u00aders, tax advi\u00adsors and tax specia\u00adlists in three offices in Berlin, Hamburg and Colo\u00adgne. www.smp.law<\/p>\n
\nDr. Frede\u00adrik G\u00e4rt\u00adner (Corpo\u00adrate), Asso\u00adciate Partner
\nJens Kretz\u00adschmann (Taxes), Partner
\nDr. Martyna Sabat (Corpo\u00adrate), Associate<\/p>\n","protected":false},"excerpt":{"rendered":"